5月28日，药明合联盘中下跌3.14%，报55.4港元/股，成交额2810.37万港元，连续多个交易日走弱。
消息面上，公司此前公告拟动用最多1亿美元内部资金在公开市场回购股份，母公司药明生物亦宣布不超过4亿美元回购计划，合计回购规模达5亿美元。然而密集回购仍未能有效提振市场信心，药明系个股整体承压，药明康德跌3.52%、药明生物跌2.73%。国泰海通维持公司"增持"评级，目标价84.38港元，看好ADC赛道增长前景。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.